DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/n5dsmq/pharmapoint) has announced the addition of the "PharmaPoint: Multiple Sclerosis - US Drug Forecast and Market Analysis to 2022" report to their offering. PharmaPoint: Multiple Sclerosis - US Drug Forecast and Market Analysis to 2022. Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying therapies (DMT). The dominance of first-line injectable DMTs, including the interferon beta (IFN) agents: Bayer's Betaseron/Betaferon (IFN-1b), Biogen's Avonex (IFN-1a) and Merck's Rebif (IFN-1a), and Teva's Copaxone (glatiramer acetate), has been a salient feature of the MS therapeutics market. However, the competitive landscape is undergoing significant change with the emergence of oral therapies, several pipeline products with notable efficacies, and looming generics/biosimilars following the patent expiries of key branded products during the forecast period. In addition, the entry of new companies such as Sanofi/Genzyme and F. Hoffmann-La-Roche/Genentech will challenge the position of the established players in the MS marketplace. The US is the largest MS market due to the high prevalence of the disease and comparatively high MS drug prices.During the forecast period, … Continue reading →

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/njkqmx/gilenya_multiple) has announced the addition of the "Gilenya (Multiple Sclerosis) - Forecast and Market Analysis to 2022" report to their offering. Gilenya (Multiple Sclerosis) - Forecast and Market Analysis to 2022. Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying therapies (DMT). The dominance of first-line injectable DMTs, including the interferon beta (IFN) agents: Bayer's Betaseron/Betaferon (IFN-1b), Biogen's Avonex (IFN-1a) and Merck's Rebif (IFN-1a), and Teva's Copaxone (glatiramer acetate), has been a salient feature of the MS therapeutics market. However, the competitive landscape is undergoing significant change with the emergence of oral therapies, several pipeline products with notable efficacies, and looming generics/biosimilars following the patent expiries of key branded products during the forecast period. In addition, the entry of new companies such as Sanofi/Genzyme and F. Hoffmann-La-Roche/Genentech will challenge the position of the established players in the MS marketplace. Novartis' Gilenya (fingolimod; FTY720) was the first FDA-approved, orally-administered DMT available for the treatment of MS. Gilenya is a synthetic analogue of the fungus Isaria sinclarii that was … Continue reading →

Arrest warrants have been issued against Zaibunissa Kazi and Sharif Parkar who have been convicted for their role in the 1993 Mumbai blasts case. The two, who were supposed to surrender before court today, failed to do so thus prompting the warrants. Mr Parkar is presently admitted to Prince Aly Khan Hospital in Byculla, Mumbai where he is due to undergo angioplasty. The 71-year-old Ms Kazi is reportedly undergoing medical treatment. Ms Kazi was ordered in Mrach by the Supreme Court to serve five years for her role in the 1993 serial bombings in Mumbai, one of the worst terror attacks in India. In April, her appeal to be given a month's reprieve before being sent to jail was granted by a Mumbai court on humanitarian and health grounds. Yesterday, celebrity actor Sanjay Dutt, also convicted in the Mumbai blasts case surrendered at a special court in Mumbai and returned to jail. He has already spent part of his five-year-sentence and has to serve 42 months more. Originally posted here: 1993 Mumbai blast case: Arrest warrant against Zaibunissa Kazi and Sharif Parkar for failing to surrender … Continue reading →

FREDERICTON - A fund set up to help multiple sclerosis patients in New Brunswick pay for so-called liberation therapy will continue, Finance Minister Blaine Higgs said Thursday, despite waning interest and questions over the efficacy of the unproven treatment. Higgs said the government decided to continue offering public money to people seeking the treatment outside Canada to fulfil a campaign promise, even though a number of studies have cast doubt about the procedure. "We want the medical professionals to help advise on that and to help us go forward on that," Higgs said. The government has budgeted $75,000 for the fund this year, on top of the $400,000 it set aside in the first two years of the program. Applicants can get $2,500 each if a community group raises matching funds for the procedure, which can cost more than $10,000. But interest in the fund has fallen short of expectations. Only $210,000 has been spent so far, Higgs said, with 84 people having received the money to pay for the treatment. Jessesar Mitchell, a spokeswoman for the MS Society's Atlantic division, said while the organization supports anyone's decision to seek the treatment, it may be wiser to spend the money … Continue reading →